Computationally repurposing drugs for breast cancer subtypes using a network-based approach

BMC Bioinformatics

Table 7 Top 20 drugs corresponding to subtype 6

Rank	Drug	Dosage (μm)	Treatment time (h)	Score	Drug type	References
1	Ruxolitinib	10	24	− 0.67	Approved	[51, 52]
2	Rupatadine	0.04	24	− 0.5	Approved
3	Maraviroc	10	24	− 0.49	Approved	[64]
4	Deferiprone	0.04	24	− 0.49	Approved	[66, 67]
5	Phentermine	0.04	24	− 0.49	Approved
6	Iniparib	10	24	− 0.48	Investigational	[108]
7	ICI-185,282	0.04	24	− 0.48	Experimental
8	Racecadotril	0.04	24	− 0.48	Investigational
9	Fingolimod	0.04	24	− 0.47	Approved	[82]
10	Amiprilose	0.04	24	− 0.47	Experimental
11	Tranilast	0.04	24	− 0.46	Investigational	[68]
12	Mibampator	0.04	24	− 0.46	Investigational
13	Favipiravir	0.04	24	− 0.45	Approved
14	Selisistat	0.04	24	− 0.45	Experimental
15	ZD-7288	10	24	− 0.45	Experimental
16	Proglumide	10	24	− 0.44	Experimental
17	TG-100801	0.04	24	− 0.44	Investigational
18	Ranolazine	0.04	24	− 0.44	Approved	[78]
19	Semaxanib	0.04	24	− 0.44	Investigational	[79]
20	Ribavirin	10	24	− 0.44	Approved	[65]

ISSN: 1471-2105